BGF | Activity | F4
BGF Activity Every public signal F4 has attached to this firm, with sources and cross-entity links.
Investment
BGF led an investment in Luffy AI, a neuroplastic AI pioneer, to drive commercialisation and convert pilots into partnerships with industry leaders. Luffy AI
BGF announced it has surpassed £5bn total invested since 2011; portfolio companies have generated £8.2bn in revenue growth and created 35,000+ jobs, with 280+ exits delivering £3.7bn in exit proceeds. BGF surpasses £5bn invested over 15 years
Milestone
BGF portfolio company Gaussion raised $28m to accelerate its ultrafast EV battery charging technology. Gaussion
Investment
BGF backed medical device company CroíValve to advance clinical evidence, regulatory plans, and further development of the DUO System. CroíValve
Investment
BGF invested in biotechnology company TRIMTECH Therapeutics to support progression of lead programmes into pre-clinical development. TRIMTECH Therapeutics
Exit
BGF exited Aberdeen-based isol8 to Archer, a global energy service business, to advance well plug and abandonment strategy. isol8
Investment
BGF backed Bristol-based eSignature platform Signable to support product development and accelerate expansion across SME and mid-market segments. Signable
Exit
BGF successfully exited Polar Technology, a carbon-fibre and metals manufacturer, to US private equity firm Trive Capital. Polar Technology
Investment
BGF made a growth investment into GovTech leader Fivium to further scale its SaaS platform and digital solutions for the public sector. Fivium
Exit
BGF successfully exited Midlands-based recruiter Metric Search, acquired by US firm Southfield Capital at a $100 million valuation. Metric Search
Investment
BGF backed pharmaceutical manufacturer Seda with a £15m investment to acquire freehold of its manufacturing facility and pursue international expansion. Seda
Investment
BGF and Development Bank of Wales backed IQ Endoscopes in a follow-on round to support the medical device company's early commercial rollout. IQ Endoscopes
News
BGF reported strong 2025 deal activity and landmark exits, returning over £600m and achieving a money multiple above 2x; paid a £75m dividend to shareholders. BGF 2025 annual results: £600m+ returned, 2x+ money multiple
Investment
BGF joined Cellular Origins' Series A, bringing the round's total funding to $40 million. Cellular Origins